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Background: Inactivation of wild type P53 by its main cellular inhibitors (MDM2 and MDMX) is a well recognised
feature of tumour formation in liposarcomas. MDM2 over-expression has been detected in approximately 80% of
liposarcomas but only limited information is available about MDMX over-expression. To date, we are not aware of
any study that has described the patterns of MDM2 and MDMX co-expression in liposarcomas. Such information
has become more pertinent as various novel MDM2 and/or MDMX single and dual affinity antagonist compounds
are emerging as an alternative approach for potential targeted therapeutic strategies.
Methods: We analysed a case series of 61 fully characterized liposarcomas of various sub-types by
immunohistochemistry, to assess the expression levels of P53, MDM2 and MDMX, simultaneously. P53 sequencing was
performed in all cases that expressed P53 protein in 10% or more of cells to rule out mutation-related over-expression.
Results: 50 cases over-expressed MDM2 and 42 of these co-expressed MDMX at varying relative levels. The relative
expression levels of the two proteins with respect to each other were subtype-dependent. This apparently affected
the detected levels of P53 directly in two distinct patterns. Diminished levels of P53 were observed when MDM2
was significantly higher in relation to MDMX, suggesting a dominant role for MDM2 in the degradation of P53.
Higher levels of P53 were noted with increasing MDMX levels suggesting an interaction between MDM2 and
MDMX that resulted in a reduced efficiency of MDM2 in degrading P53. Of the 26 cases of liposarcoma with
elevated P53 expression, 5 were found to have a somatic mutation in the P53 gene.
Conclusions: The results suggest that complex dynamic interactions between MDM2 and MDMX proteins may
directly affect the cellular levels of P53. This therefore suggests that careful characterization of both these markers
will be necessary in tumours when considering in vivo evaluation of novel blocker compounds for MDM proteins,
as a therapeutic strategy to restore wild type P53 function.
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Soft Tissue Sarcomas (STS) represent a heterogeneous
group of mesenchymal tumours from various tissues of
origin that display a spectrum of distributions across the
age groups. These relatively rare tumours account for
1% of all cancers and have a poor prognosis, due to high
recurrence rates and distant metastasis. The overall five* Correspondence: N.Touqan@leeds.ac.uk
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reproduction in any medium, provided the oryear survival of STS is 50%. This has remained unchanged
for the past 15 years [1].
Liposarcomas (LS) account for 20% of STS and are
the most common type of STS in adult life. They are
morphologically classified into five main subgroups:
well-differentiated (WDLS); de-differentiated (DDLS);
myxoid (MXLS); round cell (RCLS); and pleomorphic
(PLLS). Cytogenetically, WDLS and DDLS characteristic-
ally show amplification of the MDM2 gene [2] and MXLS/
RCLS usually have a specific chromosomal translocationl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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radical surgical excision with the use of adjuvant ra-
diotherapy for intermediate and high grade tumours.
Approximately 25% of liposarcomas present in the
retroperitoneum. At this site, efforts to achieve wide
clear surgical margins are more challenging, especially
posteriorly, due to anatomical constraints. Conven-
tional chemotherapies have an unproven role in the
neo-adjuvant setting. They are mainly prescribed for
advanced, inoperable and recurrent sarcomas, but with
no significant evidence that they provide an improved
survival rate [4]. Therefore new effective, systemic, tar-
geted therapies are clearly needed to improve the outcome
for these tumours.
P53 is a key regulator of the cell cycle, apoptosis, DNA
repair and cellular senescence [2]. Mutations or deletions
in P53 are seen in approximately 50% of all human can-
cers [5]. However, the incidence of P53 mutations in STS
had been reported to be significantly lower. Previous
analyses have estimated that only 17% of liposarcomas
have a P53 mutation [6,7]. This observation emphasises
the important role that other mechanisms probably play,
which render wild type P53 inactive in the carcinogenic
transformation of liposarcomas.
It is known that non-sarcomatous malignancies with
wild type P53 usually demonstrate a clinical pattern that
is more responsive to chemotherapy and radiotherapy
[6]. This response is not seen in liposarcomas due to the
lack of targeted therapies against specific pathways of par-
ticular significance in STS formation. The best character-
ized pathway of this type is the interaction of wild type
P53 with its main cellular inhibitors, the “murine double
minute” 2 (MDM2) and the “murine double minute” X
(MDMX) proteins [8].
MDM2 and P53 regulate each other’s functions through
an auto-regulatory feedback loop. Upon activation, P53
promotes transcription of the MDM2 gene and, in turn,
the MDM2 protein inhibits P53 activity. This inhibition is
achieved mainly through MDM2 acting as a ubiquitin E3
ligase for P53, thus targeting P53 for proteasomal degrad-
ation [9]. Although amplification of the MDM2 gene is
seen in nearly 100% of WDLS and DDLS, over-expression
of MDM2 protein is only observed in approximately 75%
of these subtypes by immunohistochemistry [10]. High
levels of MDM2 mRNA have been reported as a negative
prognostic factor in STS, including liposarcomas [11]. It
may be of prognostic significance that the phenomenon of
MDM2-mediated P53 inactivation has a predilection to
occur more often in retroperitoneal liposarcomas, com-
pared to those that arise in the extremities [12].
MDMX (also known as MDM4) is an MDM2 homolog,
which was described after MDM2 [13]. The two proteins
share striking structural similarities as both are comprised
of an N-terminal hydrophobic pocket for P53 binding, acentral acidic domain, a zinc-chelating structure and a
RING (‘really interesting new gene’) domain of a rare
C2H2C4 structural type, for potential binding to generate
heterodimers [14]. A significant body of evidence suggests
that MDMX is, in addition, an independent negative regu-
lator of P53 [15]. However, in contrast to MDM2, MDMX
lacks an intrinsic E3 ligase activity [16] due to structural
differences in its RING and central acidic domains, com-
pared to MDM2 [17]. This particular feature of MDMX
has provoked some controversy about its exact role in the
STS transformation process [18].
Some studies have demonstrated that MDMX en-
hances the effects of MDM2 by inhibiting the latter’s
self-ubiquitinylation and therefore increasing its rela-
tively short cellular half-life. As a result, MDM2 is able
to achieve increased P53 degradation [19-21]. MDMX
forms heterodimers with MDM2, which also stimulates
the ability of the latter to degrade P53 [22]. Other studies,
however, have suggested that MDMX may stabilise P53
and, in fact, antagonise the MDM2-targeted degradation
of P53 [16,23].
The mutual dependence model described by Gu
et al., in modified cell lines, suggested that the two pro-
teins rely on one another to sustain a potent P53 inhib-
ition [19]. The exact cellular functions of MDMX were
noted to vary between activation and inhibition of
MDM2 depending on the former’s relative expression
levels in relation to MDM2 [19]. This model provided
an explanation for some of the controversies surrounding
MDMX functions in cell lines, in a relatively coherent
manner. However, it has previously lacked support from
careful descriptive studies performed on actual human
sarcoma tissue.
MDMX gene amplification had been detected in 17%
of human LS [24]. Recent studies have also reported
MDMX co-amplification with MDM2 in some STS
subtypes, particularly in LS [25,26]. In addition, the
over-expression of MDM2 and/or MDMX is generally
accepted to correlate with retained wild type P53 [27].
However, previous analysis of MDMX over-expression
and of its relative co-expression with MDM2 in human
liposarcomas is lacking. In this study, we aimed to
characterize various subtypes of adult human liposarco-
mas in relation to their simultaneous expression levels
of MDM2, MDMX and P53. Such a characterization has
become a pertinent task due to the exponential growth
of MDM2/MDMX single and dual affinity blocking
compounds that have emerged in recent years as an
attractive targeted therapeutic approach [28-34]. This
characterization may also provide insights into the cel-
lular function of MDMX in liposarcomas and may guide
future functional studies to evaluate the utility of novel,
dual MDM2/MDMX blocking compounds in the treatment
of STS [35].
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Cohort
Ethical approval was obtained from the Regional Ethics
Committee (Leeds Central Research Ethics Committee),
approval number 10/H1313/34. A cohort of patients
with a fully characterized histopathological diagnosis of
liposarcoma, who provided a written informed consent,
was identified at the Leeds Teaching Hospitals NHS Trust,
UK. The total number of cases was 61 with a median age
of 64 years. Details of the clinical cohort are summarised
in Table 1.
Immunohistochemistry
Formalin-fixed, paraffin-embedded (FFPE) tissue blocks
were cut with a microtome at 4 μm thickness, to obtain
sequential sections. Sections were floated in a water
bath at 39–42°C before transfer onto Superfrost Plus
slides. Slides were incubated overnight at 37°C. Slides
were de-waxed by serial immersion in a xylene-to-ethanol
solvent gradient. Antigen retrieval was performed by im-
mersing the slides in a hot bath of 10 mM citrate buffer
(pH 6.0) at 95-98°C for 20 minutes. After cooling for
20 minutes at room temperature, the slides were washed
for 5 minutes in deionised water and a further 5 minutes
in Tris-buffered saline (TBS) (50 mM Tris.HCl, 150 mM
NaCl, pH 7.4). Endogenous peroxidase was blocked by 3%
(v/v) hydrogen peroxide for 20 minutes. Slides were
washed in TBS for 5 minutes, blocked with 20% (v/v) goat
serum in TBS for 30 minutes and then washed in TBS. In-
cubation with monoclonal primary antibodies diluted in
5% (v/v) goat serum in TBS was performed at the concen-
trations recommended by the manufacturers, as follows.
For MDM2 (Santa Cruz Biotechnology Inc., California,
USA, catalogue no. sc-965) at a dilution of 1:250 for 90 mi-
nutes; for MDMX (Bethyl Laboratories Inc., Montgomery,
USA, catalogue no. IHC-00108-1) at 1:250 dilution; and
for P53 (Leica Microsystems, Newcastle, UK, catalogue
no. NCL-L-p53-DO7) at a 1:600 dilution. Both of the
latter were incubated for 18 hours at 5°C.
To detect the primary antibodies, the NovLink Max
Polymer Detection System was used (Leica Microsystems,Table 1 The clinical cohort
Category Subcategory Result (n)
Sex Female 31
Male 30
Anatomical location Trunk 26 (12 retroperitoneal)
Extremities 35
Histological subtype WDLS 39
DDLS 9
MXLS/RCLS 12
Other 1 (Inflammatory)
Summary of the analysed clinical cohort.Newcastle, UK) according to the manufacturer’s instruc-
tions. The slides were counter-stained with haematoxylin,
dehydrated through an ethanol-to-xylene solvent gradient
and mounted under glass cover slips.
Negative control slides were analysed with each
cycle of immunohistochemistry and included simple
lipomas and normal adipose tissue from human breast
specimens.
Scoring was performed on an Olympus multi-viewer
light microscope (model number BX41) at 40x magnifi-
cation. This was done simultaneously but independently
by a trained researcher and an experienced histopatholo-
gist. Both were blinded to the actual histological diagno-
sis. 100 cells per slide were scored (maximum of 20 cells
per high power field). Particular care was taken to mark
the sequential slides of each case identically, so as to
score corresponding fields for the three different
antibodies.
Only nuclear staining was considered positive. Blood
cells, inflammatory cells, non-specific cells and capillary
endothelium cells were not included in the scoring
process. Scoring was stratified for MDM2 and MDMX
as (−, + and ++) where <10, 10–40 and >40 of the 100
cells were stained positive, respectively. P53 was con-
sidered over-expressed (+) if 10% or more cells had
positive nuclear staining. The slides were then proof
read and re-scored separately by a specialist consultant
histopathologist.
Polymerase chain reaction for P53
All 26 cases that over-expressed P53 were analysed.
DNA extraction from FFPE blocks was performed using
QI Amp® DNA FFPE Tissue Kit (Qiagen, Venlo,
Netherlands, catalogue no. 56404). The tissue blocks
were first cut using a microtome at 7 micron thickness,
the first two sections were discarded and the subsequent
3–5 sections were used, following the manufacturer’s in-
structions accurately. The resulting extract was then
quantified for nucleic acid using a NanoDrop™ 1000
Spectrophotometer. PCR for P53 exon 4 to 9 and flank-
ing intervening sequences was performed using 6 PCR
fragments covering these regions. The sequences were
aligned to reference sequence NT_010718.16 (Table 2).
PCRs were performed in 25 μl total reaction volumes
that contained 0.5 μl of each primer at 10 μM; 0.5 μl of
10 mM deoxynucleoside triphosphates (dNTP); 0.3 μl of
Taq DNA polymerase; 5 μl of 5x Go Taq flexi PCR buf-
fer (Promega, Madison, USA, catalogue no. M890);
1.5 μl of 25 mM MgCl2 (Promega, Madison, USA, cata-
logue no. A531); 2.5 μl of genomic DNA (approximately
50 ng) and brought to the total volume by adding sterile
water. Double-stranded DNA was denatured by heating
to 95°C for 3 minutes, followed by 40 cycles of the fol-
lowing steps: denaturing at 95°C for 30 seconds; cooling
Table 2 P53 primers used in the study
Exon Nucleotide sequence Size Tm°
P53 Exon 4 Forward: TCCCAAGCAATGGATGATTT 194 bp 63°C
Reverse: TTCTGGGAAGGGACAGAAGA
P53 Exon 5٭ Forward: CTCTTCCTGCAGTACTCCCCTGC 211 bp 55°C
Reverse: GCCCCAGCTGCTCACCATCGCTA
P53 Exon 6٭ Forward: GATTGCTCTTAGGTCTGGCCCCTC 182 bp 55°C
Reverse: GGCCACTGACAACCACCCTTAACC
P53 Exon 7٭ Forward: GCTTGCCACAGGTCTCCCCAAG 192 bp 59°C
Reverse: AGGCTGGCAAGTGGCTCCTGAC
P53 Exon 8٭ Forward: TGGTAATCTACTGGGACGGA 134 bp 50°C
Reverse: GCTTAGTGCTCCCTGGGGGC
P53 Exon 9٭ Forward: GCCTCTTTCCTAGCACTGCCCAAC 102 bp 50°C
Reverse: CCCAAGACTTAGTACCTGAAGGGTG
Tm°, actual annealing temperature used for each primer; ٭primers reproduced from reference [40].
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onds. The final cycle was complemented by an extension
at 72°C for 2 minutes. A negative control of all reagents
excluding genomic DNA was included in all experiments,
as was a positive control of previously analysed DNA
(from human blood). The PCR products were then puri-
fied from unincorporated oligonucleotide primers using
GenElute PCR clean up kit (Sigma Aldrich, St Louis, USA,
catalogue no. NA1020), with the manufacturer’s instruc-
tions followed accurately.Table 3 Score summary of the analysed cohort
MDMX - MDMX + MDMX ++ Total
P53 - P53 + P53 - P53 + P53 - P53 +
MDM2 - 9* 2* 0 0 0 0 11
MDM2 + 3 1 4 0 0 2† 10
MDM2 ++ 4§ 0 12§ 1§ 3† 20† 40
Total 19 17 25 61
Immunohistochemistry scores for MDM2 and MDMX were stratified as follows:
(−) normal expression: when <11% of cells had positive nuclear staining;DNA analysis
DNA analysis was performed using Sanger sequencing to
detect somatic mutations in P53. BigDye® Terminator v3.1
Cycle Sequencing Kit (Applied Biosystems Inc. [ABI],
Warrington, UK) was used where 1 μl of the template
PCR product; 4 μl of BigDye™ 3.1 master mixture and 1.6
picomoles of the corresponding primer were mixed and
the solution was brought to 10 μl by adding sterile water.
Cycle sequencing was then performed with 25 cycles of
rapid thermal ramping with the following steps: 96°C for
10 seconds; 50°C for 5 seconds; and 60°C for 4 minutes.
The sequencing reactions were visualised on an Applied
Biosystems 3130xL Genetic Analyzer. PCR reactions and
subsequent sequencing were repeated up to three times in
failed cases. Identification, verification and annotation of
sequence variants were done using GeneScreen software
(http://dna.leeds.ac.uk/genescreen) [36].(+) moderate over-expression: when 11 – 40% of cells had positive nuclear
staining; (++) strong over-expression: when >40% of cells had positive nuclear
staining. Scores for P53 were: (−) negative expression: when ≤10% of cells had
positive nuclear staining; (+) positive expression: when 11% or more of cells
had positive nuclear staining.
*MDM-P53 pathway is inactive as negative staining for MDM2 and MDMX;
§ collaborative MDM2 and MDMX pattern with higher MDM2 expression levels
resulting in negative P53; † competitive MDM2 and MDMX pattern where
comparable levels of MDM2 and MDMX expression lead to positive P53.Results
Immunohistochemistry
The 61 LS cases analysed in the cohort were comprised of
the following sub-types: 39 WDLS; 9 DDLS; 12 MXLS/
RCLS; and 1 case of inflammatory LS.As shown in Table 3, MDM2 over-expression (+/++)
was detected in 82% of cases (n = 50/61). MDMX co-
expression (+/++) was seen in 69% of cases (n = 42/61) in
varying ratios compared with MDM2. The co-expression
pattern was subtype-dependent, where WDLS displayed
abundant levels of MDM2 in relation to MDMX, whereas
all other subtypes had comparable levels of MDM2 and
MDMX expression. No solitary MDMX (without MDM2)
over-expression was detected in any of the analysed cases.
43% of cases (n = 26/61) had positive P53 expression (+).
Perhaps unexpectedly, most of these cases (n = 23/26)
co-expressed both MDM2 and MDMX as well.
Eleven cases (10 WDLS and 1 MXLS) had apparently
normal (low) MDM2 and MDMX expression levels. Two
of these cases also demonstrated P53 over-expression, sug-
gesting the presence of a possible P53 mutation. However,
only one of these two cases was found to have a P53muta-
tion on subsequent analysis.
Table 4 Summary of MDM2, MDMX, P53 over-expressions in relation to the anatomical location of LS
LS subtype Number
of cases
Retroperitoneal Non-retroperitoneal
MDM2(+/++) MDMX(+/++) P53(+) MDM2(+/++) MDMX(+/++) P53(+)
WDLS 39 4/4 2/4 0/4 26/35 19/35 9/35
DDLS 9 7/7 7/7 5/7 2/2 2/2 2/2
MXLS/ RCLS 12 1/2 1/2 1/2 8/10 10/10 9/10
No variations were detected in the expression profiles of the analysed proteins in relation to the anatomical location of LS at the time of presentation.
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MDM2, MDMX and P53 staining. A predilection to over-
express MDMX at higher relative levels was noted in all
these cases and all also had positive P53 expression.
Eight of the 29 WDLS that over-expressed MDM2 did
not co-express MDMX. This feature was not observed
in any of the other subtypes. Seven of these cases also
demonstrated negative P53 expression. This may indicate
sufficient degradation of P53 by MDM2 alone. Moreover,
P53 expression in cases that co-expressed MDM2 and
MDMX increased with increasing MDMX levels as might
have been predicted by the mutual dependence model.
The corollary was also observed, with diminished P53
levels when MDMX expression was present but only at
low levels.Figure 1 Co-expression patterns of MDM proteins in different subtyp
levels were noted across various subtypes of LS. A predilection to over-exp
WDLS, whereas all other LS subtypes had comparable MDM2 to MDMX exp
of the individual scores by independent scorers.P53 genomic analysis
All P53 positive cases on IHC (+) were subsequently
screened for somatic P53 mutations (n = 26). PCR
amplification of exon 7 failed in three of these cases. 5
cases (19%) were found to have previously described
pathological mutations: 1 missense mutation in exon 4
c.137C > T; p.S46F in a MXLS that over-expressed
MDM2 and MDMX; 3 missense mutations in exon 5
namely c.511G > A; p.E171K and c.392A > G; p.N131S
in a WDLS case that had normal MDM2 and MDMX
expression; and c.550G > A; p.D184N in two cases
(MXLS and WDLS) that over-expressed both MDM2
and MDMX. A frame shift mutation was detected in
exon 8 K292*FS (c.876DelAG) in an inflammatory
WDLS that also over-expressed MDM2 and MDMX.es of liposarcomas. Different patterns of MDM2/MDMX expression
ress MDM2 at higher levels in comparison to MDMX was a feature of
ression levels on immunohistochemistry. Data presented are the mean
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In agreement with previous reports, MDM2 over-
expression was frequently detected across the various
subtypes of LS. MDMX co-expression was also a common
feature and probably more frequent than previously re-
ported [24]. In contrast to some previous analyses [12], no
specific patterns of MDM2, MDMX or P53 expression
were noted in LS, in relation to their anatomical distri-
bution (Table 4).
The pattern of MDM2 and MDMX co-expression varied
between the different subtypes of LS, with a notable ten-
dency for higher expression levels of MDMX in all MXLS
and RCLS that over-expressed the two proteins. On the
other hand, WDLS predominantly over-expressed MDM2.
The distribution of the actual expression values across
the different subtypes of LS in the analysed cohort is
illustrated in Figure 1.
Most of the cases that did not over-express MDM2 or
MDMX had apparently normal expression levels of P53
(n = 9/11). This may indicate that the P53- MDM path-
way was intact in these cases. Therefore these bio-
markers remained at low levels and, in turn, this might
suggest a different mechanism of carcinogenesis in these
cases.
MDM2 and MDMX co-expression was noted to influ-
ence the expression levels of P53 in two distinctFigure 2 Immunohistochemistry patterns for MDM2, MDMX and P53.
identified: normal expression where none of the examined proteins was ov
comparison to MDMX (Pattern A); positive P53 expression with comparablepatterns as shown in Figure 2: A) a collaborative pattern
where diminished or no P53 expression was detected.
This pattern was mainly observed in cases where
MDMX was co-expressed with MDM2 but at relatively
lower levels (+) (§ in Table 3). This pattern could have
resulted from MDMX collaborating with MDM2 to in-
hibit P53 by targeting it for degradation, leading to dimin-
ished P53 expression, in line with MDMX acting as an
MDM2 stabiliser. Tumours with this expression pattern
may respond well to MDM2 blockers or dual specificity
antagonists of higher MDM2 affinity; B) a competitive
pattern where higher scores of P53 were observed
(>10% of cells). This pattern was mainly noted in cases
where MDMX was co-expressed at relatively high levels
(++) († in Table 3). This pattern may be explained by
MDMX possibly “competing” with MDM2 in binding to
P53, resulting in reduced P53 degradation by MDM2
and therefore higher cellular expression levels, in line
with MDMX acting, here, as a P53 stabiliser [16,37].
Tumours that express this profile may best be targeted
by dual blocker compounds. One could argue that
MDMX single affinity blockers may have a reduced
therapeutic potential in these cases, as the resulting
MDMX-freed P53 may then be subject to degradation
by the over-expressed MDM2, if no MDM2 antagonist
is used in conjunction. As no cases of LS that over-Three distinct patterns of immunohistochemistry staining were
er-expressed; negative P53 expression with higher scores of MDM2 in
scores of MDM2 and MDMX (Pattern B).
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were detected, there must be questions about the utility of
single affinity MDMX blockers in LS. However, antago-
nising MDMX-mediated P53 suppression may still have
some beneficial therapeutic effect in these cases and
functional studies will be needed to clarify this.
These observations regarding patterns of co-expression
are in agreement with the previously described mutual
dependence model from modified cell lines. Despite the
different genetic alterations involved in the malignant
transformation of the different sub-types of LS, it is
noted that the expression level of P53 was largely af-
fected by the MDM2/MDMX ratio in all sub-types, with
a statistically significant negative correlation between
MDM2/MDMX ratio and P53 expression (p < 0.001).
P53 expression in relation to the Log2(MDM2/MDMX)
scores for each histological subtype is illustrated in
Figure 3.
The P53 genomic analysis data showed a similar muta-
tion rate in cases that overexpressed P53 with those of all
LS in general as reported in the literature. 81% of theseFigure 3 P53 expressions in relation to the Log2(MDM2/MDMX) score
detected when MDMX was co-expressed at comparable or higher levels in
expression was noted when MDM2 was expressed at significantly levels th
normal expression of MDM2, MDMX and P53 were excluded from this figucases had wild type P53 suggesting that the expression
pattern of P53 in these cases is a genuine manifestation of
their MDM2-MDMX interactions.
Conclusion
Our results suggest that the dynamic co-expression of
MDM2 and MDMX proteins can directly affect cellular
levels of P53. This therefore invites a careful charac-
terization of these markers in tumours when considering
in-vivo experimental evaluation of novel MDM2-specific
or dual target MDM2/MDMX blocking compounds.
Ideally, a greater number of samples are required to defini-
tively describe the clinical consequences of the P53-MDM
interactions seen in LS tumours. However, due to the
rarity of this disease, this study along with other related
reports [38,39] can only provide an indication of the im-
portance of the P53-MDM interaction in LS. Neverthe-
less, given the lack of any current effective targeted
therapy for LS patients, we believe further functional
studies should be performed to assess the efficacy of
this therapeutic approach.s. Across various subtypes of LS, higher P53 expression levels were
relation to MDM2 (Log2(MDM2/MDMX) < 1). Diminished P53
an MDMX (Log2(MDM2/MDMX) > 1). 11 cases that had apparently
re for clarity.
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